Kyverna's cell therapy meets main goal of mid-stage study
15/12/2025 11:33
Dec 15 (Reuters) - Kyverna Therapeutics KYTX.O said on Monday its experimental cell therapy for treating patients with a rare movement disorder met the main goal of a mid-stage study. (Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Kyverna Therapeutics
See all newsHealth Rounds: Appendix removal linked with lower colon cancer risk in study
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
U.S. STOCKS ON THE MOVE-Everpure, Dropbox, Darden Restaurants